However, two randomized trials showed that potent P2Y12 inhibitors, such as ticagrelor or prasugrel, were more effective at preventing ischemic events than standard DAPT with clopidogrel in patients with acute coronary syndrome [3,4]. The gene discussed is P2RY12; the disease is acute coronary syndrome.